Program
pasritamig
Also written as “JNJ-78278343” and “Pasritamig”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Johnson & Johnson.
Furthest: phase 3, since Sep 4, 20255 company-led studies, 5 open or runningNext primary completion: Mar 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 55 open or running | phase 3since Sep 4, 2025 | May 20, 2021 | Mar 31, 2027phase 1 · NCT04898634 |
- Named in Johnson & Johnson’s own pipeline as
pasritamig
, phase 3, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2021First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04898634 · 216 enrolled · United States, China, France and more
- Oct 18, 2023Phase 1 study in Prostatic NeoplasmsNCT06095089 · 355 planned · United States, Australia, China and more
- Jul 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07082920 · 140 planned · United States, United Kingdom
- Sep 4, 2025Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07164443 · 1,203 planned · United States, Australia, Belgium and more
- Nov 6, 2025Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07225946 · 800 planned · United States, Australia, Belgium and more
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT04898634
- Jun 21, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06095089
- Nov 19, 2027Primary completion: phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07225946
- Nov 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07082920
TargetBeta
“A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administra…”NCIt, read by Claude
“A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07225946Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more | 3 | Recruiting | Nov 19, 2027 | 800 |
| NCT07164443Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more | 3 | Recruiting | Aug 18, 2028 | 1,203 |
| NCT07082920Prostatic Neoplasms · United States, United Kingdom | 1 | Recruiting | Nov 30, 2027 | 140 |
| NCT06095089Prostatic Neoplasms · United States, Australia, China and more | 1 | Recruiting | Jun 21, 2027 | 355 |
| NCT04898634Prostatic Neoplasms · United States, China, France and more | 1 | Active, not recruiting | Mar 31, 2027 | 216 |
How it is read
Names in the registry
- “JNJ-78278343”, 3 entries
- “Pasritamig”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.